Oncopeptides is a rapidly growing biopharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives.
The lead product candidate melflufen is currently being reviewed by the U.S. Food and Drug Administration, FDA, as a potential treatment for multiple myeloma. The FDA has granted the New Drug Application for melflufen a priority review and set a target date for a decision to February 28, 2021. The company is planning for a commercial launch in the US in the beginning of 2021.
Melflufen is the first drug candidate coming out of the company´s proprietary Peptide Drug Conjugate platform, PDC. Oncopeptides has recently submitted an Investigational New Drug application for its second drug candidate from this technology platform, OPD5.
Oncopeptides has established a new facility for pre-clinical drug development in Solna, Sweden, which provides adequate resources to further expand the development of the PDC-platform and generate new drug candidates.
The global headquarters is in Stockholm, Sweden, and the U.S. headquarters in Waltham, Massachusetts, outside of Boston. In addition, the company has an office in Los Altos, California.
Oncopeptides AB has 250 employees and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.